这是一篇科研论文的图注，请润色一下：Figure Legends

Figure. 1 Oral administration of QA protect liver against HFD induced liver lipid accumulation
(A) Photo of mice treated by QA in group fed ND (right) and HFD (Left). (B) Body weights, (C) Food, (D) Water intakes and (E) blood glucose of mice during 8 weeks of oral administration of QA. (F) Blood total triglyceride, (G) total cholesterol, (H) ALT levels at 4 weeks of treatment. (H) Liver weight and (I) photos of liver after sacrifice at 8 weeks of treatment. (J) H&E staining of liver section of mice fed HFD. Data were presented as mean ± SEM, * p<0.05, ** p<0.01 using Student’s T test.

Figure. 2 Oral administration of QA improves insulin sensibility of mice.
(A) Glycemia profile and (B) AUC of 2g/kg glucose tolerance test in mice treated with QA and fed ND. (C) Glycemia profile and (D) AUC of 2g/kg glucose tolerance test of HFD fed mice. (E) Glycemia profile and (F) AUC of 0.8U/kg insulin tolerance test in mice treated with QA and fed ND. (G) Glycemia profile and (H) AUC of 0.8U/kg insulin tolerance test in HFD fed mice. All experiment were carried out at 6 weeks of treatment, Data were presented as mean ± SEM, * p<0.05, ** p<0.01 using Student’s T test.

Figure. 3 Oral administration of QA increase respiratory quotient of HFD fed mice.
(A) Oxygen consumptions rates, (B) CO2 production rates and their day-night averages of mice treated with QA and fed HFD. (C) respiratory quotient, (D) locomotive activates, (E) food and (F) water intakes of mice treated with QA and fed HFD. All experiment were carried out at 8 weeks of treatment, Data were presented as mean ± SEM, * p<0.05, ** p<0.01 using Student’s T test.


Figure.4 Transcriptomic and metabolomic analysis of mice and primary hepatocytes treated by QA
(A) Top 20 DEGs and (B) KEGG enrichment analysis of mice liver treated by QA and fed ND. (C) Top 20 DEGs and (D) KEGG enrichment analysis of mice primary hepatocytes treated by 10 μmol/l QA for 24h. (E) Venn analysis of DEGs between mice liver and mice primary hepatocytes and (H) the KEGG analysis of shared DEGs. (I) The expression levels of glucose and lipid metabolism related genes in mice liver and primary hepatocytes. (G) the regulon analysis of the shared DEGs. (K) The top 20 affected metabolites and (L) KEGG enrichment analysis in the plasma of mice treated by QA and fed ND.

Figure.5 QA protect liver against HFD induced liver lipid accumulation through inhibiting liver CD36 and LPL expression and disrupt glucagon signaling.
(A) qPCR analysis of liver and (B) epididymal adipose tissues in mice treated with QA and fed ND. (C) expression levels of LPL and CD36 in mice primary hepatocytes treated by 10 μmol/l QA for 24h. (D) Endocrine hormones and cytokines levels in QA treated ND fed mice.

Figure.6 QA downstream metabolite NAD aggravate the HFD induce liver accumulation.
(A) Photo of mice treated by QA and NAD in mice fed HFD. (B) Body weights, (C) Food, (D) Water intakes and (E) blood glucose of mice during 8 weeks of oral administration of QA or NAD. (F) Blood total triglyceride, (G) total cholesterol, (H) ALT levels at 4 weeks of treatment. (H) Photos of liver after sacrifice at 8 weeks of treatment. (J) H&E staining of liver section of mice fed HFD. (J) Heat production rates, (K) locomotive activates and their day-night averages of mice treated with QA or NAD in mice fed HFD. Data were presented as mean ± SEM, * p<0.05, ** p<0.01 using Student’s T test.